Common use of Research Management Committee Clause in Contracts

Research Management Committee. The goals and progress of the research component of the Program ("Research Program") shall be determined and monitored by a Research Management Committee ("RMC"), which shall be composed of three members from each of Tularik and JT, the Chairperson of which shall be named by Tularik. A Party may replace any designee to the RMC by written notice to the other Party. The RMC shall meet at least twice annually at a time and place it so designates. The RMC will periodically review the Research Program and the Parties' progress thereunder, to the extent set forth in the Research Plan, including all screening results and new developments regarding the Field, and propose changes to the Research Plan based upon the results of prior work and new developments in the Field. The RMC will select the Collaboration Lead Compounds by a unanimous vote pursuant to Section 3(b). All data and information obtained by either Party pursuant to the Research Program will be provided to the RMC. The RMC will delegate responsibility for the filing and prosecution of Program Patents arising from the Research Program on inventions jointly discovered in the course of the Research Program Term (as defined in Section 2(g)). The RMC will be responsible for coordinating all aspects of all activities undertaken to identify and develop a Lead Compound that are necessary or desirable to determine whether such Lead Compound may be suitable for designation as a Collaboration Lead Compound pursuant to Section 3(b)(i). In addition, the RMC will be responsible for coordinating all aspects of all activities (including, but not limited to: [ * ] that will be undertaken with respect to a Collaboration Lead Compound that are necessary or desirable to enable the filing of an IND on Products based upon or incorporating such Collaboration Lead Compound, including the preparation and filing of an IND (collectively, "Pre-Clinical Development"). All decisions of the RMC shall be unanimous. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Research Management Committee. The goals and progress of the research component of the Research Program ("Research Program") shall be determined and monitored by a Research Management Committee ("RMC"), which shall be composed of three members from each of Tularik and JT, the Chairperson of which shall be named by Tularik. A Party may replace any designee to the RMC by written notice to the other Party. The RMC shall meet at least twice annually at a time and place it so designates. The RMC will periodically review the Research Program and the Parties' progress thereunder, to the extent set forth in the Research Plan, including all screening results and new developments regarding the Field, and propose changes to the Research Plan based upon the results of prior work and new developments in the Field. The RMC will select the Collaboration Lead Compounds by a unanimous vote pursuant to Section 3(b). All data and information obtained by either Party pursuant to the Research Program will be provided to the RMC. The RMC will delegate responsibility for the filing and prosecution of Program Patents arising from the Research Program on inventions jointly discovered in the course of the Research Program Term (as defined in Section 2(g))Term. The RMC will be responsible for coordinating all aspects of all activities undertaken to identify and develop a Lead Compound that are necessary or desirable to determine whether such Lead Compound may be suitable for designation as a Collaboration Lead Compound pursuant to Section 3(b)(i). In addition, the RMC will be responsible for coordinating all aspects of all activities (including, but not limited to: [ * ] that will be undertaken with respect to a Collaboration Lead Compound that are necessary or desirable to enable the filing of an IND on Products based upon or incorporating such Collaboration Lead Compound, including the preparation and filing of an IND (collectively, "Pre-Clinical Development"). All decisions of the RMC shall be unanimous. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.